A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer
A study of Cetuximabβ combined with Envolimab and mFOLFOX6 in Subjects with Advanced Colorectal Cancer
Advanced Colorectal Cancer
DRUG: Cetuximabβ combined with Envolimab and mFOLFOX6
Progression-free survival (PFS), The efficacy of solid tumors was evaluated according to RECIST v1.1, Through out the study (up to 2 years)
Objective response rate (ORR), The efficacy of solid tumors was evaluated according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)., Through out the study (up to 2 years)|disease control rate (DCR), The efficacy of solid tumors was evaluated according to RECIST v1.1, Through out the study (up to 2 years)|No Evidence of Disease, NED, Percentage of all subjects who received study treatment with no evidence of tumor presence by current investigations (pathology, imaging, molecular biology, etc.)., Through out the study (up to 2 years)|Overall survival (OS), The efficacy of solid tumors was evaluated according to RECIST v1.1, Through out the study (up to 2 years)|Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE), Adverse events will be assessed by investigator(s) according to Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)., Through out the study (up to 2 years)
Predictive biomarkers of clinical response, An assay based on the Olink platform Target 96 Inflammation Panel was performed to analyze protein markers associated with efficacy., Through out the study (up to 2 years)
A study of Cetuximabβ combined with Envolimab and mFOLFOX6 in Subjects with Advanced Colorectal Cancer